Among individuals with overweight or obesity, third-quartile dosing was not associated with increased PPH risk.<h4>Conclusion</h4>Elevated BMI was associated with greater oxytocin requirements, but risks associated with increased dosing were attenuated in individuals with higher BMI. The gene discussed is OXT; the disease is obesity due to melanocortin 4 receptor deficiency.